Photo

Photo detail

Photo courtesy of VelosBio.
VelosBio’s licensed its antibody-drug conjugate ROR1 from UCSD cancer researcher Thomas Kipps.

Stories this photo appears in:

Merck Buys VelosBio for $2.75 Billion

BIOTECH: Acquisition Will Strengthen Merck’s Oncology Pipeline

Tease photo